Targeted Therapy: How Precision Medicine Is Changing Oncology

For decades, cancer drug treatment meant chemotherapy, which attacks rapidly dividing cells throughout the body and harms healthy ones along with cancerous ones. Targeted therapy represents a different idea: identify a specific molecular feature that a cancer depends on, then design a drug to act on that feature. This is the heart of precision medicine in oncology. This article explains it as science and ongoing research, for education only. It makes no treatment claims and is not medical advice.

What targeted therapy actually targets

Targeted therapies act on specific molecules, often proteins produced by mutated genes, that drive a particular cancer's growth or survival. Instead of hitting all dividing cells, they aim at a vulnerability more specific to the tumor. The promise is a better balance of effect and side effects, because healthy cells that do not depend on the targeted molecule are less affected. This approach grew directly out of the molecular understanding of cancer captured in the hallmarks framework, which identified the specific capabilities tumors rely on (Hanahan, 2022).

How precision medicine matches drug to patient

Targeted therapy only works if the relevant feature is actually present in a given patient's tumor, which is why it depends on testing. Tumors are analyzed, often by sequencing their DNA, to find the specific alterations driving them. A drug is then chosen to match an alteration when a suitable one exists. The diagnostic test that identifies who is likely to benefit is as important as the drug itself, and the two are often developed together. This pairing of a therapy with a test is what distinguishes precision oncology from a one-size-fits-all approach.

Reaching targets once thought impossible

The field's progress is illustrated by targets long considered undruggable. The KRAS protein, one of the most common drivers of cancer, resisted direct targeting for decades until inhibitors against a specific mutated form were developed (Canon et al., 2019). Each such advance follows the same logic: a deep understanding of a tumor's dependence on a specific molecule, followed by a drug engineered to exploit that dependence. These are real scientific achievements, and several targeted therapies are approved for specific cancers, which is a matter of public regulatory record.

Established Targeted therapies that match a drug to a tumor's molecular feature are approved for specific cancers and represent real progress.

Research in progress Extending precision approaches to more cancers, and preventing the resistance that often follows, are unsettled and active research problems.

The limits: not every cancer has a target

Precision medicine is powerful but not universal. Many cancers lack a clear, single, druggable driver, and for them targeted therapy has little to offer. Even when a target exists, a tumor's genetic diversity means that not all of its cells may depend on that target, so a drug can clear part of the tumor while leaving other parts untouched. This is the practical face of tumor heterogeneity, and it limits how often a single targeted drug can produce a lasting cure.

Why resistance follows success

Targeted therapies are especially prone to a particular disappointment: a strong initial response followed by relapse as the cancer evolves around the target. Because the drug applies intense selective pressure on a specific vulnerability, cells that can bypass that vulnerability are strongly favored. Vasan, Baselga, and Hyman reviewed how resistance arises across targeted therapies and why it is so common (Vasan, Baselga, and Hyman, 2019). The mechanisms are detailed in the discussion of how cancer cells evolve resistance. This is why targeted therapy is often most effective in combination, or in sequence with other options.

What precision medicine changes, and what it does not

Precision oncology has changed how many cancers are diagnosed and treated, shifting the question from where a tumor is located to what is driving it molecularly. That shift is real and consequential. What it has not done is turn cancer into a solved problem. It works best when a tumor depends heavily on a single druggable alteration, less well when many changes drive growth, and it must contend with resistance whenever it succeeds. The honest framing is that precision medicine is a major tool among several, not a replacement for the whole toolkit.

Reading targeted-therapy claims

When a headline celebrates a targeted therapy, useful questions are which cancers and which patients it applies to, whether a companion test is required, and how durable the benefit has proven. A targeted drug that helps a defined group with a specific alteration is a real advance, even if it does nothing for cancers without that alteration. The standard any such therapy must meet is described in the founder's guide to the FDA approval process, and the broader landscape is mapped in the overview of modern cancer research.

How testing access shapes who benefits

Precision medicine depends on knowing a tumor's molecular profile, which means it depends on testing actually being done. In practice, whether a patient's tumor is sequenced, how comprehensively, and how the results are interpreted can vary widely. A targeted therapy that exists is of no use to a patient whose relevant alteration was never identified. This makes the diagnostic side of precision oncology as important as the drugs themselves, and it is an active area of attention in cancer care. The broader point is that precision medicine is a system, not just a set of drugs, and it works only when testing, interpretation, and matching all function together. As sequencing becomes more routine, more patients can in principle be matched to appropriate targeted therapies, though this also raises questions about cost, access, and how to act on findings of uncertain significance. These are practical and ongoing challenges rather than solved problems, and they sit alongside the scientific limits described throughout the cancer research library.